OAM
VRDN icon

Oxford Asset Management’s Viridian Therapeutics VRDN Stock Holding History

Oxford Asset Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-28,121
Closed -$875K – 732
2025
Q4 		$875K Buy
+28,121
New +$771K 0.32% 84
2019
Q1 		– Sell
-5,539
Closed -$252K – 2007
2018
Q4 		$252K Buy
5,539
+2,913
+111% +$168K 0.01% 1465
2018
Q3 		$218K Buy
+2,626
New +$248K ﹤0.01% 1579
2018
Q1 		– Sell
-2,052
Closed -$321K – 1906
2017
Q4 		$321K Buy
+2,052
New +$261K 0.01% 1317

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Oxford Asset Management's VRDN Position: Q1 2026 in Review

Oxford Asset Management sold out of Viridian Therapeutics (VRDN) in Q1 2026, closing a stake of 28,121 shares — an estimated $875K sold.

Oxford Asset Management first reported a position in VRDN in Q4 2017 and held it in 4 quarters. The position peaked at $875K in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Oxford Asset Management reported no remaining Viridian Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Oxford Asset Management sold 28,121 Viridian Therapeutics shares in Q1 2026, an estimated $875K.
  • Oxford Asset Management first reported a position in Viridian Therapeutics in Q4 2017 and held it in 4 quarters.
  • Oxford Asset Management's Viridian Therapeutics position peaked at $875K in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Oxford Asset Management's 13F filing for Q1 2026, filed 15 May 2026.